OpportunityTitle: Recovery Act Limited Competition:  Research to Address the Heterogeneity in Autism Spectrum Disorders (R01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: Purpose. This NIH Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits applications for the following topic areas relevant to research on the heterogeneity of Autism Spectrum Disorders (ASD): Measurement development, Biomarkers/biological signatures, Immune and central nervous systems interactions, Genetics/genomics, Environmental Risk Factors, Model development, Treatment and intervention, and Services research. This FOA provides support for the R01 grant mechanism which supports larger scale studies for which preliminary data exists and proof-of-principle has been established. Mechanism of Support. This FOA will utilize the NIH Research Project (R01) award mechanism and runs in parallel with the following FOAs of essentially identical scientific scope: 1) RFA-MH-09-171, which solicits applications under the NIH Collaborative Research Grant (R01) award mechanism; 2) RFA-MH-09-172, which solicits applications under the NIH Exploratory/Developmental Research Grant (R21) award mechanism; and 3) RFA-MH-09-173, which solicits applications under the NIH Clinical Exploratory/Developmental Research Grant (R34/Collaborative R34) award mechanism. The R21 mechanism would be used for projects that propose research in the exploratory or preliminary phases. The R34 mechanism would be used for early phases of treatment development.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;